Crestone Releases Encouraging Phase 2 Trial Results for CRS3123 ...

("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection ...

Crestone Announces Positive Data From Phase 2 Clinical Trial of ...

CRS3123 is a novel drug candidate that has demonstrated narrow spectrum and minimal disruption of normal gut microbiota in preclinical and Phase ...

Narrow-spectrum drug shows promise against C diff infection in ...

Biopharmaceutical company Crestone Pharmaceuticals last week announced positive topline results from a phase 2 trial of its investigational ...

Crestone Announces Positive Data From Phase 2 Clinical Trial of ...

Crestone, Inc. ( Crestone ) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with ...

CRS3123 for C. difficile Infection Treatment (CDI) - Crestone, Inc.

Crestone, Inc. joins the Antimicrobials Working Group · First Patient Enrolled in Phase 2 Clinical Trial + QIDP & Fast Track · NIH Funding Secured for Preclinical ...

Investigational Antibiotic for C difficile Meets Primary Endpoint

Crestone's novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.

Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel ...

Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to Treat C. difficile Infections.

C Difficile Treatment Shows Positive Results in Phase 2 Study

1. Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI). News Release. · 2. Crestone, Inc.

Boehringer Ingelheim Advances Promising Geographic Atrophy ...

As reported in the Study Record on ClinicalTrials.gov, BI 771716 met its primary safety endpoints after being delivered intravitreally in both ...

CRS 3123 - AdisInsight - Springer

09 Sep 2024 Adverse events and efficacy data from a phase II trial in Clostridium difficile infections released by Crestone ; 14 Jun 2021 CRS 3123 is still in ...

19-0021 Clinical Study C. diff Clinical Trials - Crestone, Inc.

Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial · Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123.

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

Quintiles, through Dynport Vaccine Company, is conducting the study of CRS3123. The medication is being provided by its developer, Crestone, Inc ...

Latest Hotspot - Patsnap Synapse

Crestone Releases Encouraging Phase 2 Trial Results for CRS3123 in Treating C. Difficile Infections (CDI). 9 September 2024. Crestone, Inc. ("Crestone ...

Antibiotics in the clinical pipeline as of December 2022 - Nature

MGB-BP-3 (16) (po topical) is a DNA binding antibacterial being developed by MGB Biopharma (Glasgow, UK) that successfully completed a phase-II ...

Progress in the Discovery of Treatments for C. difficile Infection

CRS3123 is currently under phase 1 clinical trial as an oral nonabsorbable agent for the treatment of CDI. This study is being conducted by the Division of ...

Crestone Pharma on LinkedIn: We're pleased to be working ...

Fredrick Ruthardt's health care facilities are currently enrolling in the phase 2 study with CRS3123: https://bit.ly/3zhg5Kb ... The paper summarizes the results ...

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant ...

... CRS3123 has started a phase 2 trial (NCT04781387). Nontraditional antibacterial agents in phase 3 clinical trials. We found two ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ...

... 2 of the Exchange Act. Large accelerated filer ... RESULTS OF. OPERATIONS. 49. BUSINESS. 55. MANAGEMENT ... Phase 2a clinical trial of ibezapolstat to ...

2023 Antibacterial agents in clinical and preclinical ... - actuamed

... 2. 2. Agents that obtained market authorization ... Results from antibiotic paediatric development ... phase (Phases 1–3 and NDAs/MAAs). 13. Fig 2 ...

Targets, Mechanisms and Resistance

... phase. II clinical study [2, 3]. 1.3 β-Lactams β ... Controlled Release, 156 (2), ... been discontinued because of unsatisfactory results from a phase 3 study; and.